First Drug Success In Slowing Previously Untreatable Form Of Multiple Sclerosis
A trial of the drug ocrelizumab has demonstrated a mensurable slowing of the primary progressive class of multiple induration ( MS ) . The effect is not very large , but for a disease that has proven so repellent to intervention in the past , any benefits note a liberal step ahead . In a separate trial , ocrelizumab outperformed live drugs for patient with the more commonrelapsing remitting MS ....